Article

Fibrin glue offers alternative to sutures

Author(s):

The use of fibrin glue during pterygium surgery has been gaining in popularity. Generally, investigators from different institutions have reported the glue to be a safe and effective alternative to sutures that can effectively reduce surgical time as well as postoperative pain and discomfort.

Some complications also have been associated with this technique, including graft displacement and dehiscence and a higher recurrence rate of the pterygia.

Three groups of investigators recently reported their findings on the use of fibrin glue in surgery.

Sathish Srinivasan, FRCSEd, FRCOphth, and Allan Slomovic, MD, from the Toronto Western Hospital, Toronto, conducted a single-center retrospective chart review. They applied fibrin glue to conjunctival autografts during primary pterygium surgery and wanted to evaluate the safety, efficacy, and complication rate following this procedure.

"Traditionally, the autografts have been sutured in place using either absorbable or nonabsorbable sutures. Fibrin glue has been receiving increasing attention recently for attaching the autografts," he added.

The fibrin glue (Tisseel, Baxter) is comprised of two components-a sealant protein made of human plasminogen, fibrinogen and fibrinonectin, and factor XIII reconstituted in a bovine aprotinin, and a sealing component made of thrombin reconstituted in calcium chloride. The components are combined and applied to the desired area, Dr. Srinivasan explained.

"An important step is to obtain an autograft that is about 1 mm more than the size of the conjunctival defect. This extra 1 mm of tissue is tucked under the cut edge of the conjunctiva to obtain good apposition," he said. "No sutures were used in the procedure. This tucking of tissue all along the cut margins of the conjunctiva improves the stability of the graft."

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.